David-Neto Elias, Lemos Francine C, Fadel Luciana M, Agena Fabiana, Sato Melissa Y, Coccuza Christiano, Pereira Lilian M, de Castro M Cristina R, Lando Valeria S, Nahas William C, Ianhez Luiz E
Renal Transplantation Unit, Hospital das Clinicas, University of São Paulo School of Medicine, São Paulo, Brazil.
Transplantation. 2007 Jul 15;84(1):50-5. doi: 10.1097/01.tp.0000267647.03550.22.
The incidence of glucose metabolism disturbances after transplantation often is based on the use of hypoglycemic agents and not on the results of glucose tolerance tests (GTTs), which may camouflage the real incidence. A lack of information also exists regarding the profile of glucose metabolism during the first year after transplant.
Oral GTT along with insulin measurements and drugs pharmacokinetics were prospectively performed at days 30, 60, 180, and 360 after transplant to diagnose disturbances of glucose metabolism after renal transplantation, in nonobese patients receiving either tacrolimus (n=55) or cyclosporine (n=29), along with mycophenolate mofetil and steroids.
The incidence of impaired glucose tolerance or diabetes mellitus reached a peak at 60 days and decreased at 1 year. It could not be adequately diagnosed using fasting plasma glucose in a decreased abnormal (>99 ng/mL) range. In both groups, insulin secretion, evaluated by the Homeostasis Model Assesment (HoMA-beta), decreased (P<0.005) from the condition of normal GTT (101+/-56%) to impaired glucose tolerance (72+/-35%) and diabetes mellitus (54+/-25%). In the cyclosporine group, insulin secretion was normal and stable throughout the study period, but in the tacrolimus group, insulin secretion recovered over time and was inversely correlated with tacrolimus exposure. Insulin resistance (HoMA-IR) did not change.
This study shows the need to perform an oral GTT at 60 days and at the end of the first year of renal transplantation to adequately diagnose impaired glucose metabolism.
移植后糖代谢紊乱的发生率通常基于降糖药物的使用情况,而非葡萄糖耐量试验(GTT)的结果,这可能掩盖了实际发生率。关于移植后第一年糖代谢情况的信息也较为匮乏。
对接受他克莫司(n = 55)或环孢素(n = 29)治疗的非肥胖肾移植患者,在移植后第30、60、180和360天前瞻性地进行口服GTT,同时检测胰岛素水平和药物药代动力学,这些患者还接受了霉酚酸酯和类固醇治疗。
糖耐量受损或糖尿病的发生率在60天时达到峰值,1年时下降。在空腹血糖降低至异常范围(>99 ng/mL)时,无法充分诊断。在两组中,通过稳态模型评估(HoMA-β)评估的胰岛素分泌,从正常GTT状态(101±56%)下降至糖耐量受损(72±35%)和糖尿病(54±25%)状态(P<0.005)。在环孢素组中,整个研究期间胰岛素分泌正常且稳定,但在他克莫司组中,胰岛素分泌随时间恢复,且与他克莫司暴露呈负相关。胰岛素抵抗(HoMA-IR)未发生变化。
本研究表明,在肾移植后60天和第一年结束时进行口服GTT,对于充分诊断糖代谢受损是必要的。